17 May 2025 : Clinical Research
Pre-Chemotherapy D-Dimer Levels as Predictors of Survival Outcomes in Advanced Gastric Cancer
Yali Du ABCDEFG 1, Xuebing Jiang AD 1, Kaifei Fu ACF 1, Chengwen Cui ACDEF 2*DOI: 10.12659/MSM.947727
Med Sci Monit 2025; 31:e947727
Table 5 Baseline characteristics before matching and after matching.
| Characteristics | Pre-PSM (n=134) | Post-PSM (n=86) | ||||
|---|---|---|---|---|---|---|
| Low pretreatment D-dimer (<1.5 ug/ml, n=89) | High pretreatment D-dimer (≥1.5 ug/ml, n=45) | P | Low pretreatment D-Dimer (<1.5 ug/ml, n=43) | High pretreatment D-Dimer (≥1.5ug/ml, n=43) | P | |
| Sex | ||||||
| Male | 70 (78.7%) | 29 (64.4%) | 0.077 | 36 (83.7%) | 29 (67.4%) | 0.079 |
| Female | 19 (21.3%) | 16 (35.6%) | 7 (16.3%) | 14 (32.6%) | ||
| Histology | ||||||
| p/d or p-m/d | 46 (95.8%) | 22 (88.0%) | 0.331 | 0 | 3 (13.0%) | 0.243 |
| m/d or m-w/d | 2 (4.2%) | 3 (12.0%) | 18 (100.0%) | 20 (87.0%) | ||
| Age | ||||||
| <60 | 34 (38.2%) | 19 (42.2%) | 0.653 | 14 (32.6%) | 17 (39.5%) | 0.500 |
| ≥60 | 55 (61.8%) | 26 (57.8%) | 29 (67.4%) | 26 (60.5%) | ||
| Pathological diagnosis | ||||||
| Adenocarcinoma | 81 (91.0%) | 41 (91.1%) | 0.495 | 42 (97.7%) | 39 (90.7%) | 0.241 |
| Signet-ring cell carcinoma | 3 (3.4%) | 3 (6.7%) | 0 | 3 (7.0%) | ||
| Others | 5 (5.6%) | 1 (2.2%) | 1 (2.3%) | 1 (2.3%) | ||
| Tumor location | ||||||
| Upper one-third | 44 (49.4%) | 15 (33.3%) | 0.025 | 15 (%) | 15 (%) | 1.000 |
| Middle one-third | 28 (31.5%) | 12 (26.7%) | 12 (%) | 12 (%) | ||
| Lower one-third | 17 (19.1%) | 16 (35.6%) | 16 (%) | 16 (%) | ||
| Whole | 0 | 2 (4.4%) | 0 | 0 | ||
| Tumor size | ||||||
| <50 cm | 84 (94.4%) | 43 (95.6%) | 1.000 | 39 (90.7%) | 42 (97.7%) | 0.360 |
| ≥50 cm | 5 (5.6%) | 2 (4.4%) | 4 (9.3%) | 1 (2.3%) | ||
| Best response | ||||||
| PR | 29 (32.6%) | 15 (33.3%) | 0.515 | 16 (37.2%) | 14 (32.6%) | 0.846 |
| SD | 45 (50.6%) | 19 (42.2%) | 18 (41.9%) | 18 (41.9%) | ||
| PD | 15 (16.9%) | 11 (24.4%) | 9 (20.9%) | 11 (25.6%) | ||
| Chemotherapy cycles | ||||||
| <8 | 38 (42.7%) | 21 (46.7%) | 0.662 | 19 (44.2%) | 21 (48.8%) | 0.665 |
| ≥8 | 51 (57.3%) | 24 (53.3%) | 24 (55.8%) | 22 (51.2%) | ||
| CEA | ||||||
| <3.5 ng/ml | 39 (44.8%) | 15 (34.9%) | 0.345 | 21 (48.8%) | 13 (31.7%) | 0.125 |
| ≥3.5 ng/ml | 48 (55.2%) | 28 (65.1%) | 22 (51.2%) | 28 (68.3%) | ||
| CA199 | ||||||
| <30 u/ml | 53 (60.9%) | 19 (44.2%) | 0.092 | 27 (62.8%) | 17 (41.5%) | 0.080 |
| ≥30 u/ml | 34 (39.1%) | 24 (55.8%) | 16 (37.2%) | 24 (58.5%) | ||
| CA724 | ||||||
| <8.2 u/ml | 54 (62.8%) | 21 (50.0%) | 0.185 | 27 (62.8%) | 20 (50.0%) | 0.273 |
| ≥8.2 u/ml | 32 (37.2%) | 21 (50.0%) | 16 (37.2%) | 20 (50.0%) | ||
| Propensity matching factors are D-dimer concentration. | ||||||